Skip to main content
Fig. 3 | Biology Direct

Fig. 3

From: Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy

Fig. 3

VEM and BOR inhibited the proliferation of AML cells. A–C CD34 + Cells derived from AML patient were treated with VEM or/and BOR for 48 h. Cell viability was determined by CCK-8 assay; D Relative expression level of BRAF was normalized to β-actin in cell lines by RT-qPCR; E–F SKM-1 cells were exposed to VEM and BOR alone, Cell viability was determined by CCK-8 assay; G SKM-1 cells were treated with VEM combined with BOR for 48 h; H Combination index values were calculated with CompuSyn software. CI < 1 indicates synergy; CI = 1 is additive; and CI > 1 means antagonism. CI, combination index; Fa, effect levels; I–J MOLM-13 cells were exposed to VEM and BOR alone; K MOLM-13 cells were treated with VEM combined with BOR for 48 h; L Combination index values were calculated with CompuSyn software. *P < .05; **P < .01; ***P < .001; ****P < .001. Data was presented as mean ± SD of three independent experiments

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us